The panel of experts reviews the use dual HER2-targeted therapy in HER2+ breast cancer.
Targeted Oncology
Articles by Targeted Oncology
Experts in breast cancer management discuss the use of anthracycline and risk of the cardiac toxicities.
Experts in polycythemia vera review data regarding the role of symptomatic improvement in overall outcome in patients with polycythemia vera.
Prithviraj Bose, MD, and colleagues discuss treatment options for high risk polycythemia vera.
The experts discuss the REACH3 trial in steroid-refractory chronic GVHD and what they hope to see in the future of treating chronic GVHD.
The experts present and discuss the case of a patient with steroid-refractory chronic GVHD and discuss treatment options.
Findings suggest that combination regimens may extend overall and progression-free survival.
The panelists discuss the role of ruxolitinib steroid-refractory acute GVHD and comment on unmet needs in treating this patient population, including fecal transplants.
Understanding the importance of having a multidisciplinary team in the treatment of acute GVHD, panelists discuss the NCCN Guidelines and REACH2 trial.
Dr Prithviraj Bose reviews treatment options in the setting of hydroxyurea failure in patients with polycythemia vera.
Experts in polycythemia vera discuss decision-making around when to initiate cytoreductive therapy in patients with low risk polycythemia vera.
Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss unmet needs in the treatment of gastrointestinal stromal tumors (GISTs) and look to the future in terms of the evolving field.
Experts discuss the role of multidisciplinary management for patients with gastrointestinal stromal tumors (GISTs).
With the treatment landscape rapidly developing with the approval of new agents and the investigation of various combination regimens, understanding the individual profiles of each agent will aid treatment selection.
Experts discuss the treatment considerations for acute GVHD, the role of molecular testing, and considerations for steroid-refractory acute GVHD.
The experts discuss a case presentation of a 50-year-old woman with acute GVHD, risk factors for GVHD, and initial treatment options.
Jamile Shammo, MD, reviews initial treatment options for patients with low risk polycythemia vera.
Dr. Ruben Mesa and panel discuss the importance of and methods for risk assessment in patients with polycythemia vera.
Experts in MPN discuss diagnostic considerations for polycythemia vera.
Prithviraj Bose, MD, reviews the case of a 57-year-old man diagnosed with polycythemia vera.
Andrew Seidman, MD, reviews the case of a 45-year-old woman with HER2+ breast cancer, and the panel discusses initial treatment.
The experts describe the SOPHIA study of margetuximab in HER2+ advanced breast cancer.
Experts have a detailed conversation on the NALA trial of neratinib and capecitabine for HER2+ metastatic breast cancer.
Presentation and considerations for relapsed HER2+ metastatic breast cancer with progressing brain metastases.
Continued data for the first-generation BTK inhibitor have demonstrated its expanding utility amid a growing treatment arsenal.
Implications for treating patients with gastrointestinal stromal tumors (GISTs) in the later lines of therapy after switching from 1 treatment to another.
Brian Van Tine, MD, PhD, and Fadi Braiteh, MD, discuss the current treatment options that are available for the treatment of gastrointestinal stromal tumor (GIST).
An overview of mutations in gastrointestinal stromal tumor (GIST) and how they can influence treatment selection.
Considerations for gastrointestinal stromal tumor (GIST) sequencing in the adjuvant setting.
Fadi Braiteh, MD, discusses sequencing in patients with resectable and unresectable gastrointestinal stromal tumors (GISTs) and explains the impact on treatment considerations.